<SEC-DOCUMENT>0001193125-24-222126.txt : 20240919
<SEC-HEADER>0001193125-24-222126.hdr.sgml : 20240919
<ACCEPTANCE-DATETIME>20240919162129
ACCESSION NUMBER:		0001193125-24-222126
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240917
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240919
DATE AS OF CHANGE:		20240919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UNIVERSAL HEALTH SERVICES INC
		CENTRAL INDEX KEY:			0000352915
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				232077891
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10765
		FILM NUMBER:		241310654

	BUSINESS ADDRESS:	
		STREET 1:		367 S GULPH RD
		CITY:			KING OF PRUSSIA
		STATE:			PA
		ZIP:			19406
		BUSINESS PHONE:		6107683300

	MAIL ADDRESS:	
		STREET 1:		367 S GULPH ROAD
		CITY:			KING OF PRUSSIA
		STATE:			PA
		ZIP:			19406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d869521d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:uhs="http://www.universalhealthservices/20240917" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2024-09-17_to_2024-09-17" name="dei:AmendmentFlag" contextRef="duration_2024-09-17_to_2024-09-17">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2024-09-17_to_2024-09-17" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-17_to_2024-09-17">0000352915</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="uhs-20240917.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-17_to_2024-09-17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000352915</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-17</xbrli:startDate> <xbrli:endDate>2024-09-17</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_1">8-K</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt:date-monthname-day-year-en" id="Fact_0">September&#160;17, 2024</ix:nonNumeric></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_2">UNIVERSAL HEALTH SERVICES, INC.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="text-transform:uppercase;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:stateprovnameen" id="Fact_3">Delaware</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_4">1-10765</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_5">23-2077891</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of<br/></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation or Organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_6">UNIVERSAL CORPORATE CENTER</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_7">367 SOUTH GULPH ROAD</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_8">KING OF PRUSSIA</ix:nonNumeric>, <span style="text-transform:uppercase;"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:stateprovnameen" id="Fact_9">Pennsylvania</ix:nonNumeric></span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_10">19406</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive office) (Zip Code)</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_11">610</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_12">768-3300</ix:nonNumeric></span></p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="Fact_14">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="Fact_18">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="Fact_20">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="Fact_22">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_23">Class&#160;B Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_24">UHS</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:exchnameen" id="Fact_25">New York Stock Exchange</ix:nonNumeric></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="Fact_16">&#9744;</ix:nonNumeric></p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;17, 2024, Universal Health Services, Inc. (the &#8220;Issuer&#8221;) and certain of its subsidiaries entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, BofA Securities, Inc., Truist Securities, Inc., U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), for the issuance and sale by the Issuer of $1,000,000,000 aggregate principal amount of senior secured notes (collectively, the &#8220;Notes&#8221;) in the following tranches:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$500,000,000 aggregate principal amount of 4.625% Senior Secured Notes due 2029; and</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$500,000,000 aggregate principal amount of 5.050% Senior Secured Notes due 2034.</p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes will be guaranteed on a senior secured basis by all of the Issuer&#8217;s existing and future direct and indirect subsidiaries that guarantee the Issuer&#8217;s senior secured credit facility or the Issuer&#8217;s other first lien obligations or any junior lien obligations (the &#8220;Subsidiary Guarantors&#8221;), and will be issued and sold pursuant to the Issuer&#8217;s and the Subsidiary Guarantors&#8217; Registration Statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-282135),</span> including the prospectus dated September&#160;16, 2024, and a related prospectus supplement dated September&#160;17, 2024 as filed with the Securities and Exchange Commission on September&#160;19, 2024 (the &#8220;Prospectus Supplement&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement includes customary representations, warranties and covenants by the Issuer and the Subsidiary Guarantors. It also provides for customary indemnification by the Issuer and the Subsidiary Guarantors, on the one hand, and the Underwriters, on the other hand, against certain liabilities arising out of or in connection with sale of the Notes and for customary contribution provisions in respect of those liabilities.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As more fully described under the caption &#8220;Underwriting (conflicts of interest)&#8221; in the Prospectus Supplement, certain of the Underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the Issuer and to persons and entities with relationships with the Issuer, for which they have received or will receive customary fees and expenses. In particular, JPMorgan Chase Bank, N.A., an affiliate of J.P. Morgan Securities LLC, acted as a joint lead arranger and acts as administrative agent under the Issuer&#8217;s senior secured credit facility, and affiliates of certain of the other Underwriters act as lenders and, in some cases, as joint lead arrangers and agents, under the Issuer&#8217;s senior secured credit facility. As a result, these affiliates of certain Underwriters will receive a portion of the proceeds of the transactions as a result of the repayment of the outstanding borrowings under the Issuer&#8217;s current tranche A term loan facility.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits</p></td></tr></table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br/>&#8195;No.&#8195;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d869521dex11.htm">Underwriting Agreement, dated as of September&#160;17, 2024, among Universal Health Services, Inc., the subsidiary guarantors named therein, and J.P. Morgan Securities LLC, BofA Securities, Inc., Truist Securities, Inc., U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC as representatives of the other several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr></table><p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>
<td style="vertical-align:bottom"/>
<td style="width:5%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Universal Health Services, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;19, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steve Filton</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Steve Filton</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial<br/>Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d869521dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNIVERSAL HEALTH SERVICES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 4.625% Senior Secured Notes due 2029 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 5.050% Senior Secured Notes due 2034 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Underwriting Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;17, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Investments, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">in
Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383
Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BofA
Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Truist Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3333 Peachtree Road NE, 11th
Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlanta, Georgia 30326 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o U.S. Bancorp Investments,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">214 N. Tryon Street, 26th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlotte, North
Carolina 28202 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550 South
Tryon Street, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlotte, North Carolina 28202 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Universal Health
Services, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the &#147;<U>Underwriters</U>&#148;), for whom J.P. Morgan Securities LLC, BofA Securities,
Inc., Truist Securities, Inc., U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC are acting as representatives (the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<U>Representatives</U>&#148;), $500,000,000 aggregate principal amount of its 4.625% Senior Secured Notes due 2029 (the &#147;<U>2029 Notes</U>&#148;) and $500,000,000 aggregate principal
amount of its 5.050% Senior Secured Notes due 2034 (the &#147;<U>2034 Notes</U>&#148; and, together with the 2029 Notes, the &#147;<U>Securities</U>&#148;). The Securities will be issued pursuant to an Indenture dated as of September&nbsp;26, 2024
(the &#147;<U>Base Indenture</U>&#148;), among the Company, the guarantors listed in Schedule 2 hereto (the &#147;<U>Subsidiary Guarantors</U>&#148;), U.S. Bank Trust Company, National Association, as trustee (the &#147;<U>Trustee</U>&#148;), and
JPMorgan Chase Bank, N.A., as collateral agent (the &#147;<U>Collateral Agent</U>&#148;), as supplemented and amended by a Supplemental Indenture to be dated as of September&nbsp;26, 2024 (the &#147;<U>Supplemental Indenture</U>&#148; and together
with the Base Indenture, the &#147;<U>Indenture</U>&#148;) among the Company, the Subsidiary Guarantors, the Trustee and the Collateral Agent, and will be guaranteed on a senior secured basis by each of the Subsidiary Guarantors (the
&#147;<U>Guarantees</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Subsidiary Guarantors hereby confirm their agreement with the several Underwriters
concerning the purchase and sale of the Securities, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with
the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<U>Securities Act</U>&#148;), a registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282135),</FONT> including a prospectus, relating to the Securities. Such registration statement, as amended at the time it became
effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;<U>Rule 430 Information</U>&#148;), is referred to
herein as the &#147;<U>Registration Statement</U>&#148;; and as used herein, the term &#147;<U>Preliminary Prospectus</U>&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any
prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term
&#147;<U>Prospectus</U>&#148; means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. Any reference in this
agreement (this &#147;<U>Agreement</U>&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be and any reference to &#147;<U>amend</U>,&#148;
&#147;<U>amendment</U>&#148; or &#147;<U>supplement</U>&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities
Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<U>Exchange Act</U>&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein
shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the time when sales of the
Securities were first made (the &#147;<U>Time of Sale</U>&#148;), the Company shall have prepared (collectively, the &#147;<U>Time of Sale Information</U>&#148;): a Preliminary Prospectus dated September&nbsp;16, 2024, and each &#147;<U>free-writing
prospectus</U>&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the offering of the Securities, the Company intends to
amend and restate the senior secured credit facilities outstanding under its Credit Agreement, dated as of November&nbsp;15, 2010 and amended and restated as of September&nbsp;21, 2012, August&nbsp;7, 2014, October&nbsp;23, 2018, August&nbsp;24,
2021 and June&nbsp;23, 2022 (as amended from time to time, the &#147;<U>Existing Credit Facilities</U>&#148;), among the Company, JPMorgan Chase Bank, N.A., as administrative agent, the lenders party thereto and certain other parties thereto, to
reflect a new replacement revolving credit facility (the &#147;<U>Revolving Facility</U>&#148;) and a new replacement tranche A term loan facility (the &#147;<U>Term Loan A Facility</U>&#148; and, together with the Revolving Facility, the
&#147;<U>Senior Credit Facilities</U>&#148;). The Company intends to use the proceeds of the offering of the Securities and the Term Loan A Facility to repay all of the outstanding $2,200&nbsp;million aggregate principal amount of the tranche A term
loan facility under the Existing Credit Facilities and accrued and unpaid interest thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities and the guarantees granted by
the Subsidiary Guarantors will be secured by first-priority liens, subject to Permitted Liens (as defined below), on certain of the Company&#146;s and the Subsidiary Guarantors&#146; assets now owned or acquired in the future by the Company and the
Subsidiary Guarantors, other than (a)&nbsp;the Company&#146;s real property, (b)&nbsp;accounts receivable sold pursuant to a Company receivables facility as permitted by the Senior Credit Facilities, and (c)&nbsp;certain other excluded assets as
described in the Indenture and the Collateral Documents (as defined below) (the &#147;<U>Collateral</U>&#148;). The Collateral will also secure on a first-priority basis the Senior Credit Facilities and the $700,000,000 principal amount of 1.650%
senior secured notes due 2026, the $800,000,000 principal amount of 2.650% senior secured notes due 2030 and the $500,000,000 principal amount of 2.650% senior secured notes due 2032 (collectively, the &#147;<U>Existing Secured Notes</U>&#148;). The
Collateral shall be described in: (a)&nbsp;with respect to personal property that constitutes Collateral, the Amended and Restated Collateral Agreement, dated as of August&nbsp;7, 2014, entered into by the Company, the Subsidiary Guarantors and the
Collateral Agent (as amended, restated, amended and restated, modified and/or supplemented to the date hereof, the &#147;<U>Base Security Agreement</U>&#148;) and the Additional Authorized Representative Joinder Agreement, to be dated as of the
Closing Date (as defined below), to be entered into by the Company, the Subsidiary Guarantors, the Collateral Agent, the Existing Authorized Representatives (as defined therein) and the Trustee as an Additional Authorized Representative (the
&#147;<U>Joinder</U>&#148; and, together with the Base Security Agreement, the &#147;<U>Security Agreement</U>&#148;); and (b)&nbsp;with respect to the grants of security interests in registrations and/or applications for trademarks, patents and
copyrights (and exclusive licenses in any of the foregoing), in the Security Agreement or, respectively, the Grant of Security Interest in Trademark Rights, dated as of August&nbsp;7, 2014, entered into by UHS of Delaware, Inc., Ascend Health
Corporation and the Collateral Agent, the Grants of Security Interest in Trademark Rights, dated as of June&nbsp;3, 2016, October&nbsp;31, 2018 and September&nbsp;21, 2020, entered into by UHS of Delaware, Inc. and the Collateral Agent, and the
Supplemental Grants of Security Interest in Trademark Rights, dated as of August&nbsp;24, 2021 and June&nbsp;23, 2022, entered into by UHS of Delaware, Inc. and the Collateral Agent (collectively, the &#147;<U>Trademark Security
Agreements</U>&#148;), the Grant of Security Interest in Copyright Rights, dated as of August&nbsp;7, 2014, entered into by UHS of Delaware, Inc., the Company, Horizon Mental Health Management, LLC and the Collateral Agent, the Grant of Security
Interest in Copyright Rights, dated as of June&nbsp;3, 2016, entered into by UHS of Delaware, Inc., the Company, Horizon Mental Health Management, LLC and the Collateral Agent, the Grant of Security Interest in Copyright Rights, dated as of
September&nbsp;21, 2020, entered into by UHS of Delaware, Inc. and the Collateral Agent and the Grant of Security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Interest in Copyright Rights, dated as of December&nbsp;4, 2020, entered into by UHS of Delaware, Inc., UHP, LP, Horizon Mental Health Management, LLC and the Collateral Agent (collectively, the
&#147;<U>Copyright Security Agreements</U>&#148;) or any Patent Security Agreement (the &#147;<U>Patent Security Agreement</U>&#148;), each, if necessary, to be amended, amended and restated or supplemented as of the Closing Date (the Trademark
Security Agreements, Copyright Security Agreements and Patent Security Agreement, together with any amendments, amendments and restatements or supplements thereof, collectively, the &#147;<U>Intellectual Property Security Agreements</U>&#148;), each
delivered or to be delivered to the Collateral Agent, granting a first-priority security interest in the Collateral, subject to Permitted Liens, to the Collateral Agent for the benefit of the First Lien Secured Parties (as defined in the Collateral
Documents). The term &#147;<U>Collateral Documents</U>,&#148; as used herein, shall mean the Security Agreement and any Intellectual Property Security Agreement. The issuance and sale of the Securities, the issuance of the Guarantees, the execution
and delivery of the Indenture and the Collateral Documents and the execution, delivery and borrowing under the Senior Credit Facilities are referred to collectively as the &#147;<U>Transactions</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of the Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Securities to the several Underwriters as provided in this Agreement, and each Underwriter, on
the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company the respective principal amount of Securities set forth
opposite such Underwriter&#146;s name in Schedule 1 hereto at a price equal to 99.357% of the principal amount thereof in the case of the 2029 Notes and at a price equal to 99.035% of the principal amount thereof in the case of the 2034 Notes plus,
in each case, accrued interest, if any, from September&nbsp;26, 2024 to the Closing Date (as defined below). The Company will not be obligated to deliver any of the Securities except upon payment for all the Securities to be purchased as provided
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the Securities as soon after the
effectiveness of this Agreement as in the judgment of the Representatives is advisable, and initially to offer the Securities on the terms set forth in the Time of Sale Information. The Company acknowledges and agrees that the Underwriters may offer
and sell Securities to or through any affiliate of an Underwriter and that any such affiliate may offer and sell Securities purchased by it to or through any Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for and delivery of the Securities will be made at the offices of Simpson Thacher&nbsp;&amp; Bartlett LLP at 10:00 A.M., New York
City time, on September&nbsp;26, 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such
payment and delivery is referred to herein as the &#147;<U>Closing Date</U>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Payment for the Securities shall be made by wire
transfer in immediately available funds to the account(s) specified by the Company to the Representatives against delivery to the nominee of The Depository Trust Company (&#147;<U>DTC</U>&#148;), for the account of the Underwriters, of one or more
global notes representing the Securities of each series (collectively, the &#147;<U>Global Notes</U>&#148;), with any transfer taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Notes will be made
available for inspection by the Representatives not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and the Subsidiary Guarantors jointly and severally acknowledge and agree
that each Underwriter is acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company and the Subsidiary Guarantors with respect to the offering of Securities contemplated hereby (including in connection with
determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company, the Subsidiary Guarantors or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the
Company, the Subsidiary Guarantors or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company and the Subsidiary Guarantors shall consult with their own advisors concerning such matters
and shall be responsible for making their own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the Underwriters shall have any responsibility or liability to the Company or the
Subsidiary Guarantors with respect thereto. Any review by the Representatives or any Underwriter of the Company, the Subsidiary Guarantors, the transactions contemplated hereby or other matters relating to such transactions will be performed solely
for the benefit of the Representatives or such Underwriter, as the case may be, and shall not be on behalf of the Company or the Subsidiary Guarantors, as the case may be, or any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company and the Subsidiary Guarantors</U>. The Company and the Subsidiary Guarantors jointly and
severally represent and warrant to each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of
any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus, at the time of filing thereof, complied in all material respects with the Securities Act and did not contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and the Subsidiary Guarantors make no representation or
warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Subsidiary Guarantors in writing by such Underwriter through the
Representatives expressly for use in any Preliminary Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Time of Sale Information</I>. The Time of Sale Information, at
the Time of Sale did not, and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company and the Subsidiary Guarantors make no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Preliminary Prospectus, the Time of Sale Information or the Prospectus. No statement of material fact included in the Prospectus has been
omitted from the Time of Sale Information and no statement of material fact included in the Time of Sale Information that is required to be included in the Prospectus has been omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer</I> <I>Free Writing Prospectus. </I>The Company and the Subsidiary Guarantors
(including their respective agents and representatives, other than the Underwriters in their capacity as such) have not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any
&#147;<U>written communication</U>&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company and the Subsidiary Guarantors or
their agents and representatives (other than a communication referred to in clauses (i)&nbsp;(ii) and (iii) below) an &#147;<U>Issuer Free Writing Prospectus</U>&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act, (ii)&nbsp;the Preliminary Prospectus, (iii)&nbsp;the Prospectus, (iv)&nbsp;the documents listed on Annex A hereto, including a Pricing Term Sheet substantially in
the form of Annex B hereto, which constitute part of the Time of Sale Information and (v)&nbsp;any electronic road show or other written communications, in each case approved in writing in advance by the Representatives. Each such Issuer Free
Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and, when taken together
with the Preliminary Prospectus filed prior to the first use of such Issuer Free Writing Prospectus, at the Time of Sale, did not, and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and the Subsidiary Guarantors make no representation or warranty with respect to any
statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Subsidiary Guarantors in writing by such Underwriter through
the Representatives expressly for use in any Issuer Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Registration Statement and Prospectus.</I> The
Registration Statement is an &#147;automatic shelf registration statement&#148; as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection
of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration
Statement has been issued by the Commission and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering has been initiated or, to the Company&#146;s knowledge, threatened by
the Commission; as of the applicable effective date of the Registration Statement and any amendment thereto, the Registration Statement complied and will comply in all material respects with the Securities Act and the Trust Indenture Act of 1939, as
amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;<U>Trust Indenture Act</U>&#148;), and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will not contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and the Subsidiary Guarantors make no representation or warranty with respect to (i)&nbsp;that part of the Registration Statement that constitutes the Statement of Eligibility and
Qualification (Form <FONT STYLE="white-space:nowrap">T-1)</FONT> of the Trustee under the Trust Indenture Act or (ii)&nbsp;any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Incorporated Documents.</I> The documents incorporated by reference in each of the Registration Statement, the Prospectus and the Time
of Sale Information, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Time
of Sale Information, when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and will not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Financial Statements.</I> The financial statements and the related notes thereto included or incorporated by reference in each of the
Registration Statement, the Time of Sale Information and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly the financial position of the
Company and its subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting
principles (&#147;<U>GAAP</U>&#148;) applied on a consistent basis throughout the periods covered thereby, and the supporting schedules included or incorporated by reference in each of the Registration Statement, the Prospectus and the Time of Sale
Information present fairly the information required to be stated therein; and the other financial information included or incorporated by reference in each of the Registration Statement, the Time of Sale Information and the Prospectus has been
derived from the accounting records of the Company and its subsidiaries and presents fairly the information shown thereby. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the
Prospectus and the Time of Sale Information fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or incorporated by
reference in each of the Registration Statement, the Time of Sale Information and the Prospectus, (i)&nbsp;there has not been any material change in the capital stock or long-term debt of the Company or any of its subsidiaries, or any dividend or
distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock (other than the Company&#146;s regular quarterly dividend and distributions by joint ventures of the Company in the ordinary course
of business), or any material adverse change, or any development involving a prospective material adverse change, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or affecting the business, properties, rights, assets, management, financial position, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither
the Company nor any of its subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the
Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in each of the Registration Statement, the Time of Sale
Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly
organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, with power and authority (corporate and other) to own their properties and conduct their business as described in the Time of
Sale Information and the Prospectus, and have been duly qualified as foreign companies or corporations, as the case may be, for the transaction of business and are in good standing under the laws of each other jurisdiction in which they own or lease
properties or conduct any business so as to require such qualification, except where the failure to be so qualified, or in good standing would not, individually or in the aggregate, have a material adverse effect on the business, properties, rights,
assets, management, financial position, stockholder&#146;s equity or results of operations or prospects of the Company and its subsidiaries taken as a whole, or on the performance by the Company and the Subsidiary Guarantors of their obligations
under this Agreement, the Securities, the Guarantees and the Collateral Documents (a &#147;<U>Material Adverse Effect</U>&#148;). The Subsidiary Guarantors set forth on Schedule 2 hereto represent all of the Company&#146;s direct and indirect
material subsidiaries, except to the extent any such direct or indirect material subsidiaries are not required to be Subsidiary Guarantors under the terms of the Senior Credit Facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Capitalization.</I> The Company had, as of the date specified, the capitalization as set forth in each of the Registration Statement,
the Time of Sale Information and the Prospectus under the heading &#147;Capitalization&#148;; and all the outstanding shares of capital stock or other equity interests of each subsidiary of the Company have been duly and validly authorized and
issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company (other than capital stock or other equity interests of the holders of minority interests in joint ventures of the
Company), free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party (other than the lien on capital stock or other equity interests of any subsidiary of the Company
securing the Existing Credit Facilities (and following the refinancing thereof, the Senior Credit Facilities) and the Existing Secured Notes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Due Authorization.</I> The Company and each of the Subsidiary Guarantors have full right, power and authority to execute and deliver
this Agreement, the Securities, the Guarantees, the Indenture and the Collateral Documents (collectively, the &#147;<U>Transaction Documents</U>&#148;) and to perform their respective obligations hereunder and thereunder; and all action required to
be taken for the due and proper authorization, execution and delivery of each of the Transaction Documents and the consummation of the transactions contemplated thereby by the Company and the Subsidiary Guarantors has been duly and validly taken.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>The Indenture. </I>The Indenture has been duly authorized by the Company and each of
the Subsidiary Guarantors and, when duly executed and delivered in accordance with its terms by each of the parties thereto, the Indenture will constitute a valid and legally binding agreement of the Company and each of the Subsidiary Guarantors
enforceable against the Company and each of the Subsidiary Guarantors in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors&#146; rights
generally or by equitable principles relating to enforceability (collectively, the &#147;<U>Enforceability Exceptions</U>&#148;), and on the Closing Date, the Indenture will conform in all material respects to the applicable requirements of the
Trust Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>The Securities and the Guarantees</I>. The Securities have been duly authorized by the Company and, when duly
executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against
the Company in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture; the Guarantees have been duly authorized by each of the Subsidiary Guarantors; and, when the Securities have
been duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be valid and legally binding obligations of each of the Subsidiary Guarantors enforceable against each of the Subsidiary
Guarantors in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Underwriting Agreement</I>. This Agreement has been duly authorized, executed and delivered by the Company and each of the Subsidiary
Guarantors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Cybersecurity; Data Protection. </I>The Company and its subsidiaries&#146; information technology assets and
equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<U>IT Systems</U>&#148;) are adequate for, and operate and perform in all material respects as required in connection with the
operation of the business of the Company and its subsidiaries as currently conducted, to the knowledge of the Company and its subsidiaries, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, reproductive health, consumer health, confidential or regulated data (&#147;<U>Personal Data</U>&#148;)) used in connection
with their businesses, and there have been no breaches, violations, outages or unauthorized uses, disclosures or acquisitions of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify
any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and
regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal
Data from unauthorized use, disclosure, access, acquisition, misappropriation or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Collateral Documents</I>. Each of the Collateral Documents has been duly authorized
by the Company and each of the Subsidiary Guarantors, to the extent a party thereto, and on the Closing Date, each of the Collateral Documents will be duly executed and delivered by the Company and each of the Subsidiary Guarantors, to the extent a
party thereto, and, when duly executed and delivered in accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company and each of the Subsidiary Guarantors, to the extent a party
thereto, enforceable against the Company and each of the Subsidiary Guarantors, to the extent a party thereto, in accordance with its terms, subject to the Enforceability Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Descriptions of the Transaction Documents; Collateral</I>. Each Transaction Document conforms or will conform as of the Closing Date in
all material respects to the description thereof contained in each of the Registration Statement, the Time of Sale Information and the Prospectus. The Collateral conforms in all material respects to the description thereof contained in each of the
Registration Statement, the Time of Sale Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Collateral Documents, Financing Statements and
Collateral</I>. After giving effect to the consummation of the Transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon execution and delivery, the Security Agreement and any of the Intellectual Property Security Agreements
will be effective to grant a legal, valid and enforceable security interest in all of the grantor&#146;s right, title and interest in the Collateral; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon due and timely filing and/or recording of the financing statements and Intellectual Property Security
Agreements, as applicable, with respect to the Collateral, the security interests granted thereby constitute or will constitute valid, perfected first-priority liens and security interests in the Collateral, to the extent such security interests can
be perfected by the filing and/or recording, as applicable, of financing statements and Intellectual Property Security Agreements for the benefit of the First Lien Secured Parties, and such security interests are or will be enforceable in accordance
with the terms contained therein against all creditors of any grantor and subject only to liens expressly permitted to be incurred or exist on the Collateral under the Indenture (&#147;<U>Permitted Liens</U>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company and the Subsidiary Guarantors own, have rights in or have the power and authority to collaterally
assign rights in the Collateral, free and clear of any liens other than the Permitted Liens. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Violation or
Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with
notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property, right or assets of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the
aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>No Conflicts. </I>The execution, delivery and performance by the Company and each of
the Subsidiary Guarantors of each of the Transaction Documents to which each is a party (including, but not limited to, the filing of any applicable financing statements pursuant to the Security Agreement and the filing of any Intellectual Property
Security Agreements), the issuance and sale of the Securities, the issuance of the Guarantees, the grant and perfection of liens and security interests in the Collateral pursuant to the Security Agreement and any Intellectual Property Security
Agreements and compliance by the Company and each of the Subsidiary Guarantors with the terms thereof and the consummation of the transactions contemplated by the Transaction Documents will not (i)&nbsp;conflict with or result in a breach or
violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset
of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject (other than any lien or encumbrance created or imposed pursuant to the Collateral Documents or the collateral documents relating to
the Existing Credit Facilities (and following the refinancing thereof, the Senior Credit Facilities) and the Existing Secured Notes), (ii) result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or
similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>No Consents Required</I>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required for the execution, delivery and performance by the Company and each of the Subsidiary Guarantors of each of the Transaction Documents to which each is a party (including, but not limited to, the
filing of any applicable financing statements pursuant to the Security Agreement or the filing of any Intellectual Property Security Agreements), the issuance and sale of the Securities and the issuance of the Guarantees, as of the date hereof, the
grant and perfection of liens and security interests in the Collateral pursuant to the Security Agreement and the Intellectual Property Security Agreements and compliance by the Company and each of the Subsidiary Guarantors with the terms thereof
and the consummation of the transactions contemplated by the Transaction Documents, except for (i)&nbsp;the registration of the Securities and the Guarantees under the Securities Act, (ii)&nbsp;the qualification of the Indenture under the Trust
Indenture Act, (iii)&nbsp;the perfection of the Collateral Agent&#146;s security interests granted pursuant to the Security Agreement, any Intellectual Property Security Agreements and the financing statements related thereto and (iv)&nbsp;such
consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Legal Proceedings.</I> Except as described in each of the Registration Statement, the
Time of Sale Information and the Prospectus, there are no legal, governmental or regulatory investigations, actions, suits or proceedings (&#147;<U>Actions</U>&#148;) pending to which the Company or any of its subsidiaries is or may be a party or to
which any property, right or asset of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a
Material Adverse Effect; no such investigations, actions, suits or proceedings are threatened or, to the best knowledge of the Company and each of the Subsidiary Guarantors, contemplated by any governmental or regulatory authority or by others; and
(i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement or the Prospectus that are not so described in the Registration Statement, the Time of Sale Information and the
Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement and the
Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Time of Sale Information and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Independent Accountants.</I> PricewaterhouseCoopers LLP, which has certified certain financial statements of the Company and its
subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United
States) and as required by the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Title to Real and Personal Property.</I> The Company and its subsidiaries have good
and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all
liens, encumbrances, claims and defects and imperfections of title except for Permitted Liens and those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries,
(ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or (iii)&nbsp;secure the Existing Credit Facilities (and following the refinancing thereof, the Senior Credit Facilities) and the
Existing Secured Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Title to Intellectual Property.</I> The Company and its subsidiaries own or possess adequate rights to use
all material patents, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights and applications for all of the foregoing, licenses and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade
secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) used in the conduct of their respective businesses; and the conduct of their respective businesses does not and will not conflict in any
material respect with any such rights of others, and the Company and its subsidiaries have not received any notice of any claim of infringement of or conflict with any such rights of others which claims, if asserted and determined adversely to the
Company or any of its subsidiaries, could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the knowledge of the Company, such rights of the Company and their subsidiaries are not being infringed,
misappropriated or otherwise violated by any person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>No Undisclosed Relationships.</I> No relationship, direct or indirect, exists between
or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each
of the Registration Statement and the Prospectus and that is not so described in such documents and in the Time of Sale Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)
<I>Investment Company Act.</I> Neither the Company nor any of the Subsidiary Guarantors is, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in each of the Registration
Statement, the Time of Sale Information and the Prospectus, will be, an &#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and
the rules and regulations of the Commission thereunder (collectively, the &#147;<U>Investment Company Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Taxes.</I>
The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof, except to the extent that extensions have been duly filed with respect thereto or
taxes are being contested in good faith and for which appropriate reserves have been established in accordance with GAAP; and except as otherwise disclosed in each of the Registration Statement, the Time of Sale Information and the Prospectus, there
is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Licenses and Permits.</I> The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued
by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their
respective businesses as described in each of the Registration Statement, the Time of Sale Information and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse
Effect; and except as described in each of the Registration Statement, the Time of Sale Information and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license,
certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>No Labor Disputes.</I> (i)&nbsp;No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or,
to the best knowledge of the Company and each of the Subsidiary Guarantors, is contemplated or threatened, and (ii)&nbsp;none of the Company or any Subsidiary Guarantor is aware of any existing or imminent labor disturbance by, or dispute with, the
employees of any of the Company&#146;s or any of its subsidiaries&#146; principal suppliers, contractors or customers, except, in the case of clause (i)&nbsp;or (ii), as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Compliance With Environmental Laws</I>. (i)&nbsp;The Company and its subsidiaries (x)&nbsp;are, and at all prior times were, in
compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions and orders relating to the protection of human health or safety, the environment, natural resources, hazardous or toxic
substances or wastes, pollutants or contaminants (collectively, &#147;<U>Environmental Laws</U>&#148;), (y) have received and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, and
(z)&nbsp;have not received notice of any actual or potential liability under or relating to any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or
contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its
subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such failure to comply, or failure to receive required permits, licenses or approvals, or cost or liability, as would not, individually or in the aggregate, have a Material
Adverse Effect; and (iii)&nbsp;except as described in each of the Registration Statement, the Time of Sale Information and the Prospectus, (x)&nbsp;there are no proceedings that are pending, or that are known to be contemplated, against the Company
or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $300,000 or more will be imposed, (y)&nbsp;the
Company and its subsidiaries are not aware of any issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants,
that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company and its subsidiaries anticipates material capital
expenditures relating to any Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Compliance With ERISA.</I> (i)&nbsp;Each employee benefit plan, within the
meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;), for which the Company, or any member of the &#147;Controlled Group&#148; (defined as any organization which, along with the
Company, is treated as a single employer within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;)) would have any liability, including, without limitation, any multiemployer plan within
the meaning of Section&nbsp;3(37) of ERISA (each, a &#147;<U>Plan</U>&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including, but not limited to, ERISA and
the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative
exemption; (iii)&nbsp;no such Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA has failed to satisfy the &#147;minimum funding standards&#148; within the meaning of Section&nbsp;412 of the Code,
whether or not waived; (iv)&nbsp;the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v) no &#147;reportable event&#148;
(within the meaning of Section&nbsp;4043(c) of ERISA) for which notice has not been waived pursuant to Section&nbsp;4043 of ERISA has occurred or is reasonably expected to occur; and (vi)&nbsp;none of the Company nor any member of the Controlled
Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Governmental Licenses</I>. Except as described in each of the Registration
Statement, Time of Sale Information and the Prospectus, (i)&nbsp;the Company and its subsidiaries possess all required permits, licenses, provider numbers, certificates, approvals (including, without limitation, certificate of need approvals),
consents, orders, certifications (including, without limitation, certification under the Medicare, Medicaid, TRICARE programs and other governmental healthcare programs in which they participate), accreditations (including, without limitation,
accreditation by The Joint Commission) and other authorizations (collectively, &#147;<U>Governmental Licenses</U>&#148;) issued by, and have made all required declarations and filings with, the appropriate federal, state, local or foreign regulatory
agencies or bodies and accreditation organizations necessary to conduct the business now operated by them (including, without limitation, Government Licenses as are required (a)&nbsp;under such federal and state healthcare laws as are applicable to
the Company and its subsidiaries and (b)&nbsp;with respect to those facilities operated by the Company or any of its subsidiaries that participate in the Medicare, Medicaid and/or TRICARE programs, to receive reimbursement thereunder), except where
the failure to possess such Governmental Licenses or to make such declarations and filings would have no Material Adverse Effect; (ii)&nbsp;the Company and its subsidiaries are in compliance with the terms and conditions of all such Governmental
Licenses, except where the failure so to comply would not have a Material Adverse Effect; (iii)&nbsp;all of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of
such Governmental Licenses to be in full force and effect would not have a Material Adverse Effect and (iv)&nbsp;none of the Company or any of its subsidiaries has received any notice of proceedings relating to the revocation, suspension or
modification of any such Governmental Licenses which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect. All of the acute care hospitals, behavioral healthcare
facilities and other facilities operated by the Company or any of its subsidiaries are &#147;providers&#148; (as defined in the Social Security Act and the regulations promulgated thereunder (collectively, &#147;<U>SSA</U>&#148;)), and all
ambulatory surgery centers, diagnostic and imaging centers, radiation and oncology centers and other healthcare operations operated by the Company, the Subsidiary Guarantors or any of their respective subsidiaries are &#147;suppliers,&#148; as
defined in the SSA, and all such providers of services and suppliers are eligible to participate in the Medicare, Medicaid and TRICARE programs. For purposes of this Agreement, &#147;<U>Medicaid</U>&#148; means any state-operated means-tested
entitlement program under Title XIX of the SSA that provides federal grants to states for medical assistance based on specific eligibility criteria, &#147;<U>Medicare</U>&#148; means that government-sponsored entitlement program under Title XVIII of
the SSA that provides for a health insurance system for eligible elderly and disabled persons including eligible persons with <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease and &#147;<U>TRICARE</U>&#148; means the healthcare program
established by the U.S. Department of Defense under Title 10, Subtitle A, Part II, Chapter 55 (10 U.S.C. &#167; 1071 et seq.) for members of the military, military retirees and their dependents, and includes the competitive selection of contractors
to financially underwrite the delivery of healthcare services under the Civilian Health and Medical Program of the Uniformed Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Accounts Receivable</I>. The accounts receivable of the Company and its subsidiaries have been adjusted to reflect material changes in
the reimbursement policies of third party payors such as Medicare, Medicaid, private insurance companies, health maintenance organizations, preferred provider organizations, managed care systems and other third party payors (including, without
limitation, Blue Cross plans). The accounts receivable, after giving effect to the allowance for doubtful accounts, relating to such third-party payors do not materially exceed amounts the Company and its subsidiaries are entitled to receive, except
as described in both the Time of Sale Information and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Prohibited Activities</I>. Except as described in both the Time of Sale Information
and the Prospectus, none of the Company, their respective subsidiaries or, to the knowledge of the Company, any officers, directors, stockholders, members, employees or other agents of the Company or any of its subsidiaries or any of the hospitals
operated by them has engaged in any activities which are prohibited under federal Medicare and Medicaid statutes, including, but not limited to, 42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7</FONT> (Program Exclusion), <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7a</FONT> (Civil Monetary Penalties), <FONT STYLE="white-space:nowrap">1320a-7b</FONT> (the Anti-kickback Statute), Sections 1395nn and 1396b (the &#147;Stark&#148; law, prohibiting certain
self-referrals), the federal TRICARE statute, 10 U.S.C. Section&nbsp;1071 et seq., the Federal Civil False Claims Act, 31 U.S.C. Sections <FONT STYLE="white-space:nowrap">3729-32,</FONT> Federal Criminal False Claims Act, 18 U.S.C. Sections 286 and
287, False Statements Relating to Health Care Matters, 18 U.S.C. Section&nbsp;1035, the Inflation Reduction Act, or the Health Insurance Portability and Accountability Act of 1996 (Public Law <FONT STYLE="white-space:nowrap">104-191),</FONT> as
amended, including as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.) or any regulations promulgated pursuant to such statutes, or related state or local statutes or
regulations or any laws or regulations regarding surprise billing and price transparency or rules of professional conduct, including but not limited to the following: (i)&nbsp;knowingly and willfully making or causing to be made a false statement or
representation of a material fact in any applications for any benefit or payment under the Medicare or Medicaid program or other federal or state healthcare program or from any third party (where applicable federal or state law prohibits such
payments to third parties); (ii) knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or payment under the Medicare or Medicaid program or other
federal or state healthcare program or from any third party (where applicable federal or state law prohibits such payments to third parties); (iii) failing to disclose knowledge by a claimant of the occurrence of any event affecting the initial or
continued right to any benefit or payment under the Medicare or Medicaid program or other federal or state healthcare program or from any third party (where applicable federal or state law prohibits such payments to third parties) on its own behalf
or on behalf of another, with intent to secure such benefit or payment fraudulently; (iv)&nbsp;knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly,
overtly or covertly, in cash or in kind (A)&nbsp;in return for referring an individual to a person for the furnishing or arranging for the furnishing of any other item or service for which payment may be made in whole or in part by Medicare or
Medicaid or other federal or state healthcare program or any third party (where applicable federal or state law prohibits such payments to third parties), or (B)&nbsp;in return for purchasing, leasing or ordering or arranging for or recommending the
purchasing, leasing or ordering of any good, facility, service or item for which payment may be made in whole or in part by Medicare or Medicaid or other federal or state healthcare program or any third party (where applicable federal or state law
prohibits such payments to third parties); (v) referring an individual to a person with which it has ownership or certain other financial arrangements or billing Medicare or Medicaid or any beneficiary of such program or other person for any
designated health service or other item or service (where applicable federal law prohibits such referrals); (vi) knowingly and willfully presenting or causing to be presented a claim for a medical or other item or service that was not provided as
claimed, or is for a medical or other item or service and the person knew or should have known the claim was false or fraudulent; (vii)&nbsp;violating any corporate integrity agreement or other agreement with any government agency (including,
without limitation, the United States Department of Justice (&#147;<U>DOJ</U>&#148;) and the Office of Inspector General of the United States Department of Health and Human Services (&#147;<U>OIG</U>&#148;); and (viii)&nbsp;violating any enforcement
initiative instituted by any governmental agency (including, without limitation, the OIG and the DOJ), except, in each case set forth in this paragraph, for any such activities which would not have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Disclosure Controls</I>. The Company and its subsidiaries each maintain an effective
system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that
material information relating to the Company and its subsidiaries required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in
the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required
disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Accounting Controls.</I> The Company and its subsidiaries each maintain systems of &#147;internal control over financial
reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general
or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible
Business Reporting Language incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. There are no
identified material weaknesses or significant deficiencies in the Company&#146;s internal controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Insurance. </I>The Company
and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are adequate to
protect the Company, its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that material capital improvements or other material
expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries, nor any
director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company and each of the Subsidiary Guarantors, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its
subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of
any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee , including of any government-owned or controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any
applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable
anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or
other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable
anti-bribery and anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Compliance with Money Laundering Laws</I>. The operations of the Company and its
subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money
laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &#147;<U>Anti-Money Laundering Laws</U>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its
subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company or any of the Subsidiary Guarantors, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or employees, nor, to the
knowledge of the Company or any of the Subsidiary Guarantors, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or
enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<U>OFAC</U>&#148;) or the U.S. Department of State and including, without limitation, the designation
as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council (&#147;<U>UNSC</U>&#148;), the European Union, His Majesty&#146;s Treasury (&#147;<U>HMT</U>&#148;), or other relevant sanctions
authority (collectively, &#147;<U>Sanctions</U>&#148;), nor is the Company, any of its subsidiaries or any of the Subsidiary Guarantors located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the Kherson, the Zaporizhzhia, and the Crimea Regions of
Ukraine, Cuba, Iran, North Korea and Syria (each, a &#147;<U>Sanctioned Country</U>&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any
person (including any person participating in the transaction, whether as underwriter, initial purchaser, advisor, investor or otherwise) of Sanctions. Since April&nbsp;24, 2019, the Company and its subsidiaries have not knowingly engaged in, are
not now knowingly engaged in and will not engage in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Solvency.</I> On and immediately after the Closing Date, the Company and the Subsidiary Guarantors (after giving effect to the
issuance and sale of the Securities and the issuance of the Guarantees and the other transactions related thereto as described in each of the Registration Statement, the Time of Sale Information and the Prospectus) will be Solvent. As used in this
paragraph, the term &#147;<U>Solvent</U>&#148; means, with respect to a particular date, that on such date (i)&nbsp;the present fair market value (or present fair saleable value) of the assets of the Company and the Subsidiary Guarantors is not less
than the total amount required to pay the liabilities of the Company and the Subsidiary Guarantors on their combined total existing debts and liabilities (including contingent liabilities) as they become absolute and matured; (ii)&nbsp;the Company
and the Subsidiary Guarantors are able to realize upon their assets and pay their debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business; (iii)&nbsp;assuming consummation of
the issuance and sale of the Securities and the issuance of the Guarantees as contemplated by this Agreement, the Registration Statement, the Time of Sale Information and the Prospectus, the Company and the Subsidiary Guarantors are not incurring
debts or liabilities beyond their ability to pay as such debts and liabilities mature; (iv)&nbsp;the Company and the Subsidiary Guarantors are not engaged in any business or transaction, and do not propose to engage in any business or transaction,
for which their property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which the Company and the Subsidiary Guarantors are engaged; and (v)&nbsp;the Company and the
Subsidiary Guarantors are not defendants in any civil action that would result in a judgment that the Company and the Subsidiary Guarantors are or would become unable to satisfy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is or would be currently prohibited, directly or indirectly, under
any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest, from repaying to the Company
any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company, except as contained in (i)&nbsp;the Existing Credit Facilities
(and following the refinancing thereof, the Senior Credit Facilities), (ii) the Existing Secured Notes, (iii)&nbsp;the Indenture, (iv)&nbsp;the Security Agreement, (v)&nbsp;certain joint venture agreements entered into by subsidiaries of the Company
that are not Subsidiary Guarantors or guarantors of the Existing Credit Facilities (and following the refinancing thereof, the Senior Credit Facilities), and (vi)&nbsp;other debt of the Company as described in &#147;Description of other
indebtedness&#151;Other UHS debt&#148; in the Registration Statement, the Time of Sale Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>No
Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter
for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>No Registration Rights</I>. No person has the right to require the Company or any of
its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>No Stabilization.</I> Neither the Company nor any of the Subsidiary Guarantors has taken, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)
<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Time of Sale Information and the Prospectus will
violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Time of Sale Information or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than
in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Statistical and Market Data</I>. Nothing has come to the attention of the Company and the Subsidiary Guarantors
that has caused the Company and the Subsidiary Guarantors to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Time of Sale Information and the Prospectus are not
based on or derived from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Sarbanes-Oxley Act</I>. There is and
has been no failure on the part of the Company or any of its directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection
therewith (the &#147;<U>Sarbanes-Oxley Act</U>&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Status Under the Securities Act</I>. The Company is not an ineligible issuer and is a well-known seasoned issuer, in each case as
defined under the Securities Act, in each case at the times specified in the Securities Act in connection with the offering of the Securities. The Company has paid or will pay the registration fee for this offering pursuant to Rule 457 under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company and the Subsidiary Guarantors</U>. The Company and each of the Subsidiary
Guarantors jointly and severally covenant and agree with each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company and the
Subsidiary Guarantors will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including the Pricing Term Sheet referred to in Annex B hereto) to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus
is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior
to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. The Company has paid or will pay the registration fees for this offering within the
time period required by Rule 456(b)(1)(i) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representatives, two signed copies of the
Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of
the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus
(including all amendments and supplements thereto and documents incorporated by reference therein) and each Issuer Free Writing Prospectus as the Representatives may reasonably request. As used herein, the term &#147;<U>Prospectus Delivery
Period</U>&#148; means such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be
delivered but for Rule 172 under the Securities Act) in connection with sales of the Securities by any Underwriter or dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<I>Amendments or Supplements; Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration
Statement or the Prospectus, whether before or after the time that the Registration Statement becomes effective the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus,
amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing,
(i)&nbsp;when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Prospectus or any Issuer Free Writing Prospectus or
any amendment to the Prospectus or any Issuer Free Writing Prospectus has been filed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any
comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order
suspending the effectiveness of the Registration Statement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preventing or suspending the use of any Preliminary Prospectus, the Prospectus, any Time of Sale Information or any Issuer Free Writing Prospectus or the initiation or threatening of any
proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Time of Sale Information
or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing when the Prospectus, the Time of Sale Information or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; (vii)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of
the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (viii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities
for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the
Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Time of Sale Information, Issuer Free Writing Prospectus or the Prospectus, or suspending any such qualification of the Securities and, if any such
order is issued, will obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Time of Sale Information.</I> If at any time prior to the
Closing Date (i)&nbsp;any event shall occur or condition shall exist as a result of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company will
immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate,
such amendments or supplements to the Time of Sale Information (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in any of the Time of Sale Information as so amended or
supplemented (including such documents to be incorporated by reference therein) will not, in the light of the circumstances under which they were made, be misleading or so that any of the Time of Sale Information will comply with law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Ongoing Compliance of the Prospectus</I>. If during the Prospectus Delivery Period (i)&nbsp;any event shall occur or condition shall
exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances
existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and,
subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Prospectus (or any document to be filed with the Commission
and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (including such documents to be incorporated by reference therein) will not, in the light of the circumstances existing
when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Blue Sky Compliance.</I> The Company will qualify the Securities for offer and sale
under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Securities; <U>provided</U> that none of the
Company nor any of the Subsidiary Guarantors shall be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file
any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Earning Statement. </I>The Company will make generally available to its security holders and the Representatives as soon as practicable
an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company
occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Clear Market.</I> During
the period from the date hereof through and including the Closing Date, the Company and each of the Subsidiary Guarantors will not, without the prior written consent of the Representatives, offer, sell, contract to sell or otherwise dispose of any
debt securities issued or guaranteed by the Company or any of the Subsidiary Guarantors and having a tenor of more than one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
<I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in each of the Registration Statement, the Time of Sale Information and the Prospectus under the heading &#147;Use of proceeds.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>DTC</I>. The Company will assist the Underwriters in arranging for the Securities to be eligible for clearance and settlement through
DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>No Stabilization.</I> None of the Company nor any of the Subsidiary Guarantors will take, directly or indirectly, any action
designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free
Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Perfection of
Security Interests</I>. The Company and each Subsidiary Guarantor (i)&nbsp;shall complete on or prior to the Closing Date all filings and other similar actions required in connection with the perfection of security interests in the Collateral as and
to the extent contemplated by the Indenture and the Collateral Documents and (ii)&nbsp;shall take all actions necessary to maintain such security interests and to perfect security interests in any Collateral acquired after the Closing Date, in each
case as and to the extent contemplated by the Indenture and the Collateral Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Senior Credit Facilities</I>. Prior to, on or as promptly as practicable after the
Closing Date, the Company and the Subsidiary Guarantors will enter into the amendment and restatement of the Senior Credit Facilities, consistent in all material respects with the terms described in the Time of Sale Information and the Prospectus,
and the Company and the Subsidiary Guarantors will deliver to the Representatives conformed counterparts thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain
Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that it has not and will not use, authorize use of, refer to, or participate in the planning for use of, any &#147;<U>free writing prospectus</U>,&#148; as defined in
Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other
than (i)&nbsp;a free writing prospectus that, solely as a result of use by such Underwriter, would not trigger an obligation to file such free writing prospectus with the Commission pursuant to Rule 433, (ii) any Issuer Free Writing Prospectus
listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing
(each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;<U>Underwriter Free Writing Prospectus</U>&#148;). Notwithstanding the foregoing, the Underwriters may use the Pricing Term Sheet referred to in Annex B hereto
without the consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to
purchase Securities on the Closing Date as provided herein is subject to the performance by the Company and each of the Subsidiary Guarantors of their respective covenants and other obligations hereunder and to the following additional conditions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect,
and no proceeding for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been
timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the
Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company and the Subsidiary Guarantors contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the
Company, the Subsidiary Guarantors and their respective officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Downgrade.</I> Subsequent to the earlier of (A)&nbsp;the Time of Sale and (B)&nbsp;the execution and delivery of this Agreement,
(i)&nbsp;no downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization,&#148; as such term is defined under Section&nbsp;3(a)(62) of the Exchange Act and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its
rating of the Securities or of any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive implications of a possible upgrading). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Material Adverse Change.</I> No event or condition of a type described in
Section&nbsp;3(g) hereof shall have occurred or shall exist, which event or condition is not described in each of the Time of Sale Information (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement
thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of
Sale Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Officers&#146; Certificate.</I> The Representatives shall have received on and as of the
Closing Date a certificate or certificates of the chief executive officer and the chief financial officer of the Company and a senior officer of each Subsidiary Guarantor who has specific knowledge of such Subsidiary Guarantor&#146;s financial
matters and is satisfactory to the Representatives (i)&nbsp;confirming that such officer has carefully reviewed the Registration Statement, the Time of Sale Information and the Prospectus and, to the best knowledge of such officer, the
representations set forth in Sections 3(b) and 3(d) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company and the Subsidiary Guarantors in this Agreement are true and correct and that the
Company and the Subsidiary Guarantors have complied with all agreements and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date and (iii)&nbsp;to the effect set forth in paragraphs (a), (c)
and (d)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date, PricewaterhouseCoopers LLP shall
have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing
statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of
the Registration Statement, the Time of Sale Information and the Prospectus; <U>provided</U> that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than three business days
prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company.</I>
Norton Rose Fulbright US LLP, counsel for the Company and the Subsidiary Guarantors, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated
the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex C hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion of the General Counsel</I>. Matthew D. Klein, Senior Vice President and General Counsel to the Company, shall have furnished to
the Representatives, at the request of the Company, his written opinion, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex D hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Opinion of the Local Counsel</I>. Childs Watson, PLLC, counsel for the Company and
the Subsidiary Guarantors in the State of Nevada, shall have furnished to the Representatives, at the request of the Company, its written opinion, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representatives, to the effect set forth in Annex E hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Opinion and
<FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The Representatives shall have received on and as of the Closing Date an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement of Simpson
Thacher&nbsp;&amp; Bartlett LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable
them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>No Legal Impediment to Issuance.</I> No action shall have been taken and no statute, rule,
regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the
Guarantees; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date satisfactory evidence as of a then recent date
of the good standing (or similar status) of the Company and the Subsidiary Guarantors in their respective jurisdictions of organization and their good standing (or similar status) in such other jurisdictions as the Representatives may reasonably
request, in each case in writing or any standard form of telecommunication, from the appropriate governmental authorities of such jurisdictions, except where the appropriate governmental authority of an applicable jurisdiction does not furnish such
evidence or where the failure to be in good standing would not, individually or in the aggregate, have a material impact on the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>DTC</I>. The Securities shall be eligible for clearance and settlement through DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>CFO Certificate</I>. The Underwriters shall have received on the date of this Agreement and on the Closing Date certificates of the
chief financial officer of the Company, in form and substance satisfactory to the Representatives, with respect to certain financial data contained in each of the Time of Sale Information and the Prospectus, providing &#147;management comfort&#148;
with respect to such information, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Exhibit A hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Indenture and Securities</I>. The Indenture shall have been duly executed and delivered by a duly authorized officer of the Company,
each of the Subsidiary Guarantors, the Trustee, and the Securities shall have been duly executed and delivered by a duly authorized officer of the Company and duly authenticated by the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Lien Searches</I>. The Representatives shall have received the results of a recent lien search in each of the jurisdictions where
assets of the Company and the Subsidiary Guarantors are located (for purposes of the New York UCC) and any jurisdictions in which valid filings with respect to such assets of the Company and the Subsidiary Guarantors may be in effect, and such
search shall reveal no liens on any of the assets of the Company and the Subsidiary Guarantors or their respective subsidiaries except for Permitted Liens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Security Agreement and Intellectual Property Security Agreements</I>. The
Underwriters shall have received conformed counterparts of the Security Agreement and each of the Intellectual Property Security Agreements that shall have been executed and delivered by duly authorized officers of each party thereto, in form and
substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>Filings, Registration and Recordings</I>. Except as otherwise
contemplated by any Intellectual Property Security Agreements and the Security Agreement, each document (including any Uniform Commercial Code financing statement and any Intellectual Property Security Agreements) required by such Intellectual
Property Security Agreements and the Security Agreement, or under law or reasonably requested by the Representatives, in each case, to be filed, registered or recorded, or delivered for filing on or prior to the Closing Date, including filings, if
applicable, in the U.S. Patent and Trademark Office and the U.S. Copyright Office in order to create in favor of the Collateral Agent for the benefit of the First Lien Secured Parties, a perfected first-priority lien and security interest in the
Collateral that can be perfected by the making of such filings, registrations or recordations, prior and superior to the right of any other person (other than Permitted Liens), shall be executed if applicable, and in proper form for filing,
registration or recordation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Certificated Securities</I>. On the Closing Date, the Collateral Agent shall have received all
certificated securities and blank, undated stock powers for each of the applicable Subsidiary Guarantors as set forth in the Security Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Transactions</I>. Concurrently with or prior to the Closing Date, the Transactions shall have been consummated in a manner consistent
in all material respects with the descriptions thereof in the Registration Statement, Time of Sale Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)
<I>Additional Documents.</I> On or prior to the Closing Date, the Company and the Subsidiary Guarantors shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company and each of the Subsidiary Guarantors jointly and
severally agree to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and
expenses are incurred), joint or several, that arise out of, or are based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a
material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or
supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale Information, or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in
reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company and the Subsidiary Guarantors.</I> Each Underwriter agrees, severally and not jointly, to indemnify and
hold harmless the Company, each of the Subsidiary Guarantors, each of their respective directors and officers who signed the Registration Statement and each person, if any, who controls the Company or any of the Subsidiary Guarantors within the
meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of,
or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale Information, it being understood and agreed that the only such
information consists of the following paragraphs in the Preliminary Prospectus and the Prospectus: the fifth paragraph, the ninth paragraph and the eleventh paragraph, in each case, found under the heading &#147;Underwriting&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b) above, such person (the &#147;<U>Indemnified Person</U>&#148;) shall promptly notify the person against
whom such indemnification may be sought (the &#147;<U>Indemnifying Person</U>&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under paragraph (a)&nbsp;or
(b) above except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not
relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph (a)&nbsp;or (b) above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the
Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the
Indemnified Person and any others entitled to indemnification pursuant to this Section&nbsp;7 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses of such proceeding and shall pay the fees and expenses of
such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the
Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are
different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation
of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in
the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be reimbursed as they are incurred. Any such separate
firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives, and any such separate firm for the Company, the Subsidiary Guarantors, their
respective directors and officers who signed the Registration Statement and any control persons of the Company and the Subsidiary Guarantors shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or
liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as
contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person
of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified
Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not
include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<I>Contribution.</I> If the indemnification provided for in paragraph (a)&nbsp;or (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying
Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion
as is appropriate to reflect the relative benefits received by the Company and the Subsidiary Guarantors on the one hand and the Underwriters on the other from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause
(i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company and the Subsidiary Guarantors on the one hand and
the Underwriters on the other in connection with the statements or omissions that resulted in such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Subsidiary Guarantors on the one hand and the
Underwriters on the other shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Securities and the total underwriting discounts and commissions received
by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Securities. The relative fault of the Company and the Subsidiary Guarantors on the one
hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Company or any Subsidiary Guarantor or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company, the Subsidiary Guarantors and the Underwriters agree that it would not be just and equitable
if contribution pursuant to this Section&nbsp;7 were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include,
subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this Section&nbsp;7, in no event shall an Underwriter be
required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to their respective purchase obligations
hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this
Section&nbsp;7 are not exclusive and shall not limit any rights or remedies that may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on the New York Stock Exchange or the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company or any of the Subsidiary Guarantors shall have been suspended on any exchange or in any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there
shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes
it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder,
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours
after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within which to
procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Securities on such terms. If other persons become obligated or agree to purchase the Securities of a defaulting
Underwriter, any of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion of counsel for the Company
or counsel for the Underwriters may be necessary in the Registration Statement, the Time of Sale Information and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the
Registration Statement, the Time of Sale Information and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;<U>Underwriter</U>&#148; includes, for all purposes of this Agreement unless the context otherwise
requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;9, purchases Securities that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate principal amount of such Securities that remains unpurchased does not exceed
<FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate principal amount of all the Securities, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the
aggregate principal amount of Securities that such Underwriter agreed to purchase hereunder plus such Underwriter&#146;s <U>pro</U> <U>rata</U> share (based on the aggregate principal amount of Securities that such Underwriter agreed to purchase
hereunder) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after
giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the
aggregate principal amount of such Securities that remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate principal amount of all the Securities, or if the Company shall not exercise the right described in
paragraph (b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;9 shall be
without liability on the part of the Company or the Subsidiary Guarantors, except that the Company and each of the Subsidiary Guarantors will continue to be liable for the payment of expenses as set forth in Section&nbsp;10 hereof and except that
the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a
defaulting Underwriter of any liability it may have to the Company, the Subsidiary Guarantors or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company and each of
the Subsidiary Guarantors jointly and severally agree to pay or cause to be paid all costs and expenses incident to the performance of their respective obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the
authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the
Preliminary Prospectus, any Issuer Free Writing Prospectus, any Time of Sale Information and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the costs of reproducing and
distributing each of the Transaction Documents; (iv)&nbsp;the fees and expenses of the Company&#146;s and the Subsidiary Guarantors&#146; counsel and independent accountants; (v)&nbsp;the fees and expenses incurred in connection with the
registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum
(including the related fees and expenses of counsel for the Underwriters); (vi) any fees charged by rating agencies for rating the Securities; (vii)&nbsp;the fees and expenses of the Trustee, the Collateral Agent and any paying agent (including
related fees and expenses of any counsel to such parties); (viii) the fees and expenses incurred with respect to creating, documenting and perfecting the security interests in the Collateral as contemplated by the Collateral Documents (including the
related fees and expenses of counsel to the Underwriters for all periods prior to and after the Closing Date); (ix) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, the Financial
Industry Regulatory Authority, and the approval of the Securities for book-entry transfer by DTC; and (x)&nbsp;all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;8, (ii) the Company for any reason fails to tender the Securities for
delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company and each of the Subsidiary Guarantors jointly and severally agree to reimburse the Underwriters
for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and
the offering contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and
be binding upon the parties hereto and their respective successors and any controlling persons referred to herein, and the affiliates, officers and directors of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is
intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter shall be deemed to be a
successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Survival</U>. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company, the Subsidiary Guarantors and the Underwriters contained in this Agreement or made by or on behalf of the Company, the Subsidiary Guarantors or the Underwriters pursuant to this Agreement or any certificate
delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company, the
Subsidiary Guarantors or the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where
otherwise expressly provided, the term &#147;<U>affiliate</U>&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;<U>business day</U>&#148; means any day other than a day on which banks are permitted or
required to be closed in New York City; and (c)&nbsp;the term &#147;<U>subsidiary</U>&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Authority of the Representatives.</I> Any action by the Underwriters hereunder may be taken by the Representatives on behalf of the Underwriters, and any such action taken by the Representatives shall be binding upon the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT
STYLE="white-space:nowrap">834-6081),</FONT> Attention: Investment Grade Syndicate Desk; BofA Securities, Inc., 114 West 47<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NY8-114-07-01,</FONT></FONT></FONT> New York, NY 10036 (fax: (212) <FONT STYLE="white-space:nowrap">901-7881),</FONT> Attention: High Grade Debt
Capital Markets Transaction Management/Legal; Truist Securities, Inc., 3333 Peachtree Road NE, 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Atlanta, Georgia 30326 (fax: (404) <FONT STYLE="white-space:nowrap">926-5027),</FONT>
Attention: Investment Grade Capital Markets; U.S. Bancorp Investments, Inc., 214 North Tryon Street, 26<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Charlotte, North Carolina 28202 (fax: (704)
<FONT STYLE="white-space:nowrap">335-2393),</FONT> Attention: Debt Capital Markets; and Wells Fargo Securities, LLC, 550 South Tryon Street, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Charlotte, North Carolina 28202, Attention:
Transaction Management, Email: tmgcapitalmarkets@wellsfargo.com. Notices to the Company and the Subsidiary Guarantors shall be given to them at 367 South Gulph Road, P.O. Box 61558, King of Prussia, PA 19406-0958 (fax: (610) <FONT
STYLE="white-space:nowrap">382-4407),</FONT> Attention: Chief Financial Officer. The Company shall be entitled to act and rely upon any request, consent, notice or agreement given or made on behalf of the Underwriters by the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company and each of the Subsidiary Guarantors hereby submit to the exclusive jurisdiction of the
U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the Transactions. The Company and each of the Subsidiary Guarantors waive any
objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of the Company and each of the Subsidiary Guarantors agrees that final judgment in any such suit, action or proceeding brought in
such court shall be conclusive and binding upon the Company and each Subsidiary Guarantor, as applicable, and may be enforced in any court to the jurisdiction of which Company and each Subsidiary Guarantor, as applicable, is subject by a suit upon
such judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Waiver of Jury Trial</I>. Each of the parties hereto hereby waives any right to trial
by jury in any suit or proceeding arising out of or relating to this Agreement or the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Governing Law.</I> This
Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; &#147;delivery,&#148; and words of like import
in or relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal
effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by
electronic means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15(g): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>BHC Act Affiliate</U>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance
with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Entity</U>&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 47.3(b); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Default Right</U>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance
with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S. Special Resolution Regime</U>&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Headings.</I> The
headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UNIVERSAL HEALTH SERVICES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steve Filton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Steve Filton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Vice President and</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Each of the Subsidiary Guarantors Listed on Schedule 2 hereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steve Filton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Steve Filton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>J.P. MORGAN SECURITIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Som Bhattacharyya</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Som Bhattacharyya</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Executive Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>BOFA SECURITIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Douglas A. Muller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Douglas A. Muller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>TRUIST SECURITIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ileana I. Chu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Ileana I. Chu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>U.S. BANCORP INVESTMENTS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William J. Carney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: William J. Carney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>WELLS FARGO SECURITIES, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Carolyn Hurley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Carolyn Hurley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Principal<BR>Amount of</B><br><B>2029 Notes to<BR>be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Principal<BR>Amount of</B><br><B>2034 Notes to<BR>be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Investments, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NatWest Markets Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fifth Third Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMBC Nikko Securities America, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KeyBanc Capital Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UHS Subsidiary Guarantors </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ABS LINCS KY, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ABS LINCS SC, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aiken Regional Medical Centers, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alliance Health Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mississippi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alternative Behavioral Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ascend Health Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Atlantic Shores Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AZ Holding 4, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Arizona</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beach 77 LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Behavioral Health Management, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Behavioral Health Realty, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Behavioral Healthcare LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Benchmark Behavioral Health System, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Utah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Alhambra Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Belmont Pines Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">16.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Fairfax Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">17.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Fox Run Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">18.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Fremont Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">19.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Health Services of Nevada, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">20.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Heritage Oaks Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">21.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">22.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Intermountain Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC of Indiana, General Partnership</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">24.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Mesilla Valley Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">25.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Montevista Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">26.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Northwest Psychiatric Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">27.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Pinnacle Pointe Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">28.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Properties, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">29.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Sierra Vista Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">30.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BHC Streamwood Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">31.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bloomington Meadows, General Partnership</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">32.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brentwood Acquisition, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">33.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brentwood Acquisition-Shreveport, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">34.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brynn&nbsp;Marr Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">North Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">35.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Calvary Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">36.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canyon Ridge Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">37.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CAT Realty, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">38.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CAT Seattle, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">39.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CCS/Lansing, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michigan</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">40.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cedar Springs Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">41.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Children&#146;s Comprehensive Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">42.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Columbus Hospital Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">43.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Coral Shores Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">44.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cumberland Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">45.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cumberland Hospital Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">46.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Del Amo Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">47.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DHP 2131 K St, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">48.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Diamond Grove Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">49.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">District Hospital Partners, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">District of Columbia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">50.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DVH Hospital Alliance LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">51.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Emerald Coast Behavioral Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">52.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fannin Management Services, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">53.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Hospital Corporation of Virginia Beach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">54.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fort Duncan Medical Center, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">55.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Forest View Psychiatric Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michigan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">56.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fort Lauderdale Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">57.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FRN, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">58.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frontline Behavioral Health, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">59.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frontline Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">60.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frontline Residential Treatment Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">61.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Garfield Park Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Illinois</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">62.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Great Plains Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Missouri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">63.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gulf Coast Treatment Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">64.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gulph Mills Associates, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">65.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">H.C. Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alabama</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">66.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">H.C. Partnership</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alabama</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">67.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Harbor Point Behavioral Health Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">68.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Havenwyck Hospital Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michigan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">69.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Augusta, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Georgia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">70.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Delaware, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">71.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Indiana, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">72.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Ohio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ohio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">73.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Pennsylvania, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">74.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC Poplar Springs, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">75.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC River Park, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">West Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">76.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC South Carolina, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">77.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HHC St. Simons, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Georgia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">78.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hickory Trail Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">79.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Holly Hill Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">80.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Horizon Health Austin, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">81.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Horizon Health Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">82.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Horizon Health Hospital Services, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">83.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Horizon Mental Health Management, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">84.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HSA Hill Crest Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alabama</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">85.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hughes Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">86.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independence Physician Management, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">KEYS Group Holdings LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">88.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone/CCS Partners LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">89.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Continuum LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">90.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Education and Youth Services, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">91.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Marion, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">92.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Memphis, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">93.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Newport News, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">94.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone NPS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">95.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone Richland Center LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ohio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">96.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Keystone WSNC, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">North Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">97.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kids Behavioral Health of Utah, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Utah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">98.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kingwood Pines Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">KMI Acquisition, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">100.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">La Amistad Residential Treatment Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">101.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lancaster Hospital Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">102.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Laurel Oaks Behavioral Health Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">103.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lebanon Hospital Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">104.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Liberty Point Behavioral Healthcare, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">105.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Manatee Memorial Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">106.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mayhill Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">107.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">McAllen Hospitals, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">108.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">McAllen Medical Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">109.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Merion Building Management, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">110.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Meridell Achievement Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">111.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michigan Psychiatric Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michigan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">112.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Millwood Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">113.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milwaukee Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wisconsin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">114.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Neuro Institute of Austin, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">115.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">North Spring Behavioral Healthcare, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">116.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Northern Indiana Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">117.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Northwest Texas Healthcare System, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">118.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oak Plains Academy of Tennessee, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">119.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ocala Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">120.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Palm Point Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">121.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Palmetto Behavioral Health Holdings, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">122.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Palmetto Behavioral Health System, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">123.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Palmetto Lowcountry Behavioral Health, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">124.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Park Healthcare Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">125.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pasteur Healthcare Properties, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">126.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pendleton Methodist Hospital, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">127.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania Clinical Schools, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">128.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Premier Behavioral Solutions, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">129.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Premier Behavioral Solutions of Florida, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">130.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PSJ Acquisition, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">North Dakota</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">131.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Psychiatric Realty, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">132.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Psychiatric Solutions, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">133.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Psychiatric Solutions Hospitals, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">134.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Psychiatric Solutions of Virginia, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">135.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ramsay Managed Care, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">136.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ramsay Youth Services of Georgia, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">137.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ridge Outpatient Counseling, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kentucky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">138.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">River Oaks, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Louisiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">139.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riveredge Hospital Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">140.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riverside Medical Clinic Patient Services, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">141.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rolling Hills Hospital, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">142.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RR Recovery, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">143.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Salt Lake Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">144.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Salt Lake Psychiatric Realty, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">145.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Samson Properties, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">146.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Schick Shadel of Florida, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">147.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shadow Mountain Behavioral Health System, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">148.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">SHC-KPH,</FONT> LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">149.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Southeastern Hospital Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">150.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SP Behavioral, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">151.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sparks Family Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">152.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Springfield Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">153.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stonington Behavioral Health, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">154.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Summit Oaks Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Jersey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">155.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sunstone Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">156.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TBD Acquisition, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">157.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TBD Acquisition II, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">158.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TBJ Behavioral Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">159.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Temecula Valley Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">160.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Temple Behavioral Healthcare Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">161.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee Clinical Schools, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">162.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas Cypress Creek Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">163.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas Hospital Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">164.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas Laurel Ridge Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">165.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas Oaks Psychiatric Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">166.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas San Marcos Treatment Center, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">167.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas West Oaks Hospital, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">168.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Arbour, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">169.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Bridgeway, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Arkansas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">170.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The National&nbsp;Deaf&nbsp;Academy, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">171.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Three&nbsp;Rivers Behavioral Health, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">172.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Three Rivers Healthcare Group, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">South Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">173.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Toledo Holding Co., LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">174.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Turning Point Care Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Georgia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">175.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Two Rivers Psychiatric Hospital, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">176.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UBH of Oregon, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">177.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UBH of Phoenix, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">178.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UBH of Phoenix Realty, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">179.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHP LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">180.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Capitol Acquisition, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">181.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Children Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">182.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Funding, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">183.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Holding Company, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">184.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Kentucky Holdings, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">185.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Midwest Behavioral Health LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">186.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Anchor, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">187.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Benton, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">188.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Bowling Green, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">189.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Centennial Peaks, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">190.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Cornerstone, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">191.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Cornerstone Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">192.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of D.C., Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">193.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Delaware, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">194.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Denver, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">195.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Dover, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">196.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Doylestown, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">197.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Fairmount, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">198.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Fuller, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">199.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Georgia, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">200.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Georgia Holdings, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">201.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Greenville, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">202.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Hampton, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Jersey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">203.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Hartgrove, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Illinois</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">204.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Lakeside, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">205.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Lancaster, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">206.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Laurel Heights, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">207.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Madera, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">208.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of New Orleans, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Louisiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">209.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Oklahoma, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oklahoma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">210.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Parkwood, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">211.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Peachford, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Entity Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction of Formation</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">212.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Pennsylvania, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pennsylvania</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">213.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Phoenix, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">214.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Provo Canyon, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">215.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Puerto Rico, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">216.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Ridge, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">217.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of River Parishes, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Louisiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">218.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Rockford, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">219.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Salt Lake City, L.L.C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">220.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Savannah, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">221.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Spring Mountain, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">222.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Springwoods, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">223.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of SummitRidge, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">224.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Texoma, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">225.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Timberlawn, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Texas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">226.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Timpanogos, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">227.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Tucson, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">228.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Westwood Pembroke, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">229.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS of Wyoming, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">230.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Oklahoma City LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oklahoma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">231.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Sahara, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">232.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHS Sub III, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">233.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">UHS-Corona,</FONT> Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">234.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHSL, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">235.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UHSD, L.L.C.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">236.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United HealthCare of Hardin, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">237.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">University Behavioral, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">238.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Universal Health Services of Palmdale, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">239.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Universal Health Services of Rancho Springs, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">240.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">University Behavioral Health of El Paso, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">241.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valle Vista, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">242.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valle Vista Hospital Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tennessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">243.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valley Health System LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">244.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valley Hospital Medical Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nevada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">245.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wekiva Springs Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">246.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wellington Regional Medical Center, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">247.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wellstone Regional Hospital Acquisition, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indiana</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">248.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Willow Springs, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">249.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Windmoor Healthcare Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">250.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Windmoor Healthcare of Pinellas Park, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">251.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wisconsin Avenue Psychiatric Center, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">252.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zeus Endeavors, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Florida</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time of Sale Information </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pricing Term Sheet, dated September&nbsp;17, 2024, substantially in the form of Annex&nbsp;B.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Term Sheet </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed pursuant to Rule 433 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-282135</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Supplement dated September&nbsp;17, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Preliminary Prospectus Supplement dated September&nbsp;16, 2024 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g869521g0919091014155.jpg" ALT="LOGO" STYLE="width:2.05069in;height:0.847917in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNIVERSAL HEALTH SERVICES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>$500,000,000 4.625% Senior Secured Notes due 2029 </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>$500,000,000 5.050% Senior Secured Notes due 2034 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Pricing Supplement is qualified in its entirety by reference to the preliminary prospectus supplement dated September&nbsp;16, 2024 (the
&#147;Preliminary Prospectus Supplement&#148;) supplementing the base prospectus dated September&nbsp;16, 2024 (the &#147;Base Prospectus&#148;) included in registration statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-282135)</FONT>
filed with the Securities and Exchange Commission (the &#147;SEC&#148;) . The information in this Pricing Supplement supplements the Preliminary Prospectus Supplement and updates and supersedes the information in the Preliminary Prospectus
Supplement and the Base Prospectus to the extent inconsistent with the information therein. Terms used but not defined herein have the meanings assigned in the Preliminary Prospectus Supplement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issuer:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Universal Health Services, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Security Description:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.625% Senior Secured Notes due 2029 (&#147;2029 notes&#148;)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">5.050% Senior Secured Notes due 2034 (&#147;2034 notes&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Aggregate Principal Amount:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$500,000,000 of 2029 notes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">$500,000,000 of 2034
notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Coupon:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.625% for the 2029 notes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">5.050% for the 2034
notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Maturity:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;15, 2029 for the 2029 notes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">October&nbsp;15, 2034 for the 2034 notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Public Offering Price:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">99.957% of the principal amount for the 2029 notes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">99.685% of the principal amount for the 2034 notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Yield to Maturity:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.634% for the 2029 notes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">5.090% for the 2034
notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Spread to Treasury:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+120 basis points for the 2029 notes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+145 basis
points for the 2034 notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Benchmark Treasury:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.625% UST due August&nbsp;31, 2029 for the 2029 notes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3.875% UST due August&nbsp;15, 2034 for the 2034 notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Benchmark Treasury Yield:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.434% for the 2029 notes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3.640% for the 2034
notes</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Interest Payment Dates:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;15 and October&nbsp;15 of each year, beginning on April&nbsp;15, 2025 for the 2029 notes</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">April&nbsp;15 and October&nbsp;15 of each year, beginning on April&nbsp;15, 2025 for the
2034 notes</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Optional Redemption:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2029 notes may be redeemed, in whole or in part, at any time prior to September&nbsp;15, 2029 at the option of the Issuer, at a price
equal to 100% of the principal amount thereof, plus accrued and unpaid interest and additional interest, if any, plus a &#147;make-whole&#148; premium calculated at the applicable Treasury Rate plus 20 basis points.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The 2034 notes may be redeemed, in whole or in part, at any time prior to July&nbsp;15,
2034 at the option of the Issuer, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest and additional interest, if any, plus a &#147;make-whole&#148; premium calculated at the applicable Treasury Rate plus 25
basis points.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Change of Control Offer Following Downgrade from Investment Grade Ratings:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Upon certain change of control events, if the notes have ceased to have investment grade ratings (including as a result of entering into an agreement that would result in such a change of control), each holder may require the Issuer
to repurchase at 101%, plus accrued and unpaid interest, if any, as described in the Preliminary Prospectus Supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CUSIP:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2029 notes: 913903BB5</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2034 notes: 913903BC3</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ISIN:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2029 notes: US913903BB57</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2034 notes: US913903BC31</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Distribution:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">SEC-Registered</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Trade Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">September&nbsp;17, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Settlement:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T+7 (September 26, 2024)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are
required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the date that is one business day before the closing off the offering will be required,
by virtue of the fact that the notes initially will settle T+7, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of notes who make such trades should consult their own
advisors.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Denominations/Multiple:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$2,000 and integral multiples of $1,000 in excess thereof</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Joint Book-Running Managers:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">J.P. Morgan Securities LLC, BofA Securities, Inc., Truist Securities, Inc., U.S. Bancorp Investments, Inc., Wells Fargo Securities, LLC, Goldman Sachs&nbsp;&amp; Co., LLC, Mizuho Securities USA LLC, NatWest Markets Securities Inc.,
PNC Capital Markets LLC, and TD Securities (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Senior <FONT STYLE="white-space:nowrap">Co-Managers:</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Third Securities, Inc. and SMBC Nikko Securities America, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Co-Managers:</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">KeyBanc Capital Markets Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expected Ratings*:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moody&#146;s: Baa3</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">S&amp;P: BBB-</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Trustee:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">U.S. Bank Trust Company, National Association</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision
or withdrawal at any time.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This communication does not constitute an offer to sell or the solicitation of an offer to buy any
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Issuer has filed
a registration statement, including a base prospectus and a preliminary prospectus supplement, with the SEC for the offering to which this communication relates. Before you invest, you should read the base prospectus in that registration statement,
the preliminary prospectus supplement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov.
Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the base prospectus and preliminary prospectus supplement if you request it by calling J.P. Morgan Securities LLC collect at (212) <FONT
STYLE="white-space:nowrap">834-4533,</FONT> BofA Securities, Inc. toll-free at (800) <FONT STYLE="white-space:nowrap">294-1322,</FONT> Truist Securities, Inc. toll-free at (800) <FONT STYLE="white-space:nowrap">685-4786,</FONT> U.S. Bancorp
Investments, Inc. toll-free at (877) <FONT STYLE="white-space:nowrap">558-2607</FONT> and Wells Fargo Securities, LLC toll-free at (800) <FONT STYLE="white-space:nowrap">645-3751.</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Opinion of Norton Rose Fulbright US LLP </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[omitted.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Opinion of the General Counsel </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[omitted.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Local Counsel Opinion </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[omitted.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Chief Financial Officer Certificate </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[omitted.] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>uhs-20240917.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 74.0.3 -->
<!-- Creation date: 9/19/2024 1:46:52 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:uhs="http://www.universalhealthservices/20240917"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.universalhealthservices/20240917"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uhs-20240917_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uhs-20240917_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>uhs-20240917_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 74.0.3 -->
<!-- Creation date: 9/19/2024 1:46:52 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 2</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>uhs-20240917_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 74.0.3 -->
<!-- Creation date: 9/19/2024 1:46:51 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="uhs-20240917.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g869521g0919091014155.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g869521g0919091014155.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 ,(# 2(  A$! Q$!_\0
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M5S;,X,!W?3(KD8]+US6[O<+2[N)9#RYC8_F:]K\ >#U\):;+>Z@Z+=2KER2
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*SJN["BBBK,3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45970559766320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 17,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UNIVERSAL HEALTH SERVICES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-10765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">23-2077891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">UNIVERSAL CORPORATE CENTER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">367 SOUTH GULPH ROAD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">KING OF PRUSSIA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">19406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-3300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;B Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UHS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000352915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MH=NLH//Z3N0X(B-#):X@_)T8XU]_L7O6;P!?I^+K0.IU !>'G#3!P<T'5\\
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "N@C-9)!Z;HJT
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M2P$"% ,4    " "N@C-9!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *Z",UG O9XN[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M *Z",UF97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ KH(S6>[SI/IE!   -1$  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M *Z",UF?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ KH(S69>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ KH(S61PX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *Z"
M,UDD'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *Z",UEED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d869521d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d869521d8k.htm">d869521d8k.htm</File>
    <File>uhs-20240917.xsd</File>
    <File>uhs-20240917_lab.xml</File>
    <File>uhs-20240917_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d869521d8k.htm": {
   "nsprefix": "uhs",
   "nsuri": "http://www.universalhealthservices/20240917",
   "dts": {
    "inline": {
     "local": [
      "d869521d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "uhs-20240917.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "uhs-20240917_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "uhs-20240917_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-17_to_2024-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d869521d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-17_to_2024-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d869521d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "terseLabel": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.universalhealthservices//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-222126-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-222126-xbrl.zip
M4$L#!!0    ( *Z",UEQV1NH"!,  /-S   .    9#@V.34R,60X:RYH=&WM
M/?MSVDC2O^]?,<5>;NTJ7@+\P@Y7A)"$V\1V@;V[W_=+:I &F(V0=#,C&^ZO
MO^X924B\;8.=[-I5MI'FU=/O[FF)BW]-QBZY8T)RWWO[BU4L_T*89_L.]X9O
M?VGV6IW.+_]J_'0Q4M -NGJR[BA14-. R;>YD5)!O52ZO[\O3OK"+?IB6(+F
M$C:7*N5*I5"N%JI6+AHY<;GW+3/JOJK'6&=G9R7=&G==Z)G,7RF7JR5L[E/)
MXN[A* M-Z''<$W5'C+IJ))FXXS:3"%.M?&:=)!!)O@P>6,,J_?'E<\\>L3$M
M<$\JZMFSU918"=M9"5KCCESZM8IULF8C48]DP&157POZ>K!M]L>[[N=9=[6\
M_ZQK20GJR8$OQE0!B1$#Y4*Y4K JJ4D*DMF9B>"Z./3OULYC'17*IVGJPN)\
MW5;GL(BMSFQ NO-QR33&71TVUR^&#QIP1]6$,G*.-0=4]O6L<4NFNQ1J5?^D
M*3U@->^B?.103AAUX)_BRF6-T\*O%R7S\:>+,5.4X/ "^T_([][F6KZGF*<*
M-[!*CMCFZFU.L8DJZ>E*,*ID)B2$7/1]9]JX</@=D6KJLK<YA\O I=.ZYWLL
MUR 7?%+'WDQ$G[GC,,]\ABZ7X9@);A/NO,U]TDU? 7M?FV/F.?"K/KAT^-4)
MA2;O5Q240OFL8)U\57[J*D<\.L:U&:]GAD8[F*@N&T#SQGD: ^I*=E'* +<)
MV+8'V)RV8$E!W8[GL,FO;/HPH)=.\6#@R_!3/:J<64>+.RC-X5ZP 1.@4YF$
M:U1<=:G5"JRU3[VH5T(.?IN3?!RXR;V1P$V"QBS$VK XD4[<2H4M?.2NS6N4
MHLUF-JBOI1\*<ZF50CW"KB;G%MB-AS%-J^22.WACP)D@&H-LJ<IJ=7[-TF=^
M,$*]=/X ".@[R25H*Z'>4\4:,]CBD;.V&:S.BKYQ2[)LLDXI@YT$FS/LE=(B
M70+1AW\I!8"C"M3E0Z]NPUZ8R&7;[[FC1O73XA'WSE-]7390YV,JAMPKX.<Z
MH:'RXSN"#T?1K5SC(HCG0CM0&#'="%Y"D,R@_*">NNS[2OEC?:?O"X \OF,%
M$R)]ESODY[+^R37^^;-U7#Z_* 4KUJEN7J?RV'52L]9@#K((/AD 70J2_Y?5
MK=/D>D#'W)W6;_B827+)[DG7'U/O7+?=&[#[ONN<+Z'-[67GIOV>]&Z:-^W>
M2FC*SP1-K]VZ[79N.NT>:5Z^)^T_6I^:EQ_;I'7UY4NGU^M<73X%Q,HN0/R=
MRA'XH<KW\N1]L54DE?)1[2P+UFS-TRUX,LT+FT1I.4\>/XHGBV7HEF7+<R.=
M%>O-XM:WE,X47VOEL)18I\_$3Q^NNE_(A0RHEZB?$5>L '=L!A;R7M  D)JU
M[S.[_-ZW0_0E4M[0UN98VY4/U%9?K9QQNK(V^:*$8#5>&6?7C+,3*0<UU&U?
MWI!N^_JJ>_/B2N<Z%#*DGB+*)SUF(^<9=%E5<M4EUM&!<_CB0/H#<C-B"%\H
MN.(POCVQ1]0;,M*T%8%FZZQ:6PGF<Y$6_1X$ILL"7RAR$%\S"GX/DXJP.^A)
MA&YFSF%]WO]?U _7VGEJ&Y_JP8K"Q*]O<Q#SUAV8H#"&\2-<I>#0:6$*@!68
MEU(HX#WT6*#8N,]$Q 8G>8)3+BJ95^VR4^U2J>V"!5<RE D$NVS():8VU"6T
M/-[P5+1[]UN[VVM^)I_:S<\WGTBOW?VMTVKW\J1SV2JNYY>'Z9#R+C!ST)X
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MT$UH:R^22[Y(R,I 4%?1.7)*?"OM' ^TA>?*!KESNWLU_H3NT*I$VT0(D&3
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MNP#%C&1/F5X6BTM<B7_8ZQ8O?V^?DZ6NV_[H[MBPBGP*@YRP*;8H8-4]PW_
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MQL:6B&XFR/Q+X$D8:Z_PYL#*LN42M$U8!@I]FY$\;R1Y  >4 .I.M1NAB.<
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M!$_H"=X-XY)#PG:^G&'$33/-BY:/FA8N)+WNZ#SDPO&B=X6<<\7F*>5>@1#
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M5)AU2QSUP9'1([9J2UYHZ/#XZ"#9>VRQ'(Q ?H%!3O(XQC+B>'3-,1,[*&D
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MNP7#37 ;=USK:!_%R,8<>&GD.J6D#^MK,U^0#&@C3"#$" @.Y]%C)XYYK 5
MX14%81VSYM[*@THN62E3HI",FHGDV*E:E WXD%GM83U*$1%C/M)&66;8(CYD
M.PF?Q]5%FIN6U/(-+"HK;7U-,6'UC;4*C".9 3S.2M ]M-U&_Y"=U1U#VT5:
MO'J<J:&";]@G\OB[3^16N>UBX?HA+)(K3,U\)[[]00#V70B:W/K/)5G,=C!
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M7@"CI*8,PIP*\A90M-U++%TE;%)YS22N\S[NW9"18WF2L2.1FSA(\'>63B3
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M%4QG[W51D*7C !+E\A7(INB1A3SBD-&&M'X[>GP2H ZI/@5+W'OV\$6XO%7
MOCGW=E.YF>()-Z(4(5I%**K?Y$QN.F:_$*:W";8GNI!DDE1L\+H*?UMW[]0L
MU'H)RPC=M_7%/5SZRTL.*F#,M9(L=D1J93?S\Z1.C"RL"?GJ@@RY96K1I^O:
M)!M?P]LKM@T-EG#CP<&>DG;Y$,5S6M-G+_F>"21(+>- ZOD:C$:LN/'(-D#
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M9*#0,-+J_Q;EI^@4PT(K8)4E>8\.#WXY.(A.]O_8CUO/(%.-C?IK _(SD/9
MMP188<IW_,/0+GE\,SD2_D(*L,HO&RT.I_PR9=@"Y;R2@L@;ZAY50/EP\@(6
M[@1&X*8]? 3B8N=P=R?;[?=W[AB+.MCOB+7X@MU&F;0.%J.?T</I"&R\4N7
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M"KL\#&;:D;8%LFDK6\E!U"Z[S4_&(UU4C[QRON[Z-(2:36BLOJ !Q?? M\>
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MS3V@)^L\&<6P'@&;"OZOS5)[LM_Q(=X!Y9,(N:E9T&($((E^??GVS0>K(E_
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M>][WYL_!:I_UH\F;TX6/.#?E/K%O:N/5?V=!N5W7SY8!%6OSJ17#V9 &F^5
MJ[4 M.W*G>=HQI)M:>-GF1"MLW(G!IEG6XJ[G"XHLQ,%?N"+(PGB5SR@QBM*
M,W:]=QD7:IT3P624'F3&08_':%$+K>C#H 0]H$ *Q6MDP7%5>S893%:$?;C
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MM XXL$8"C1ZLJ>M3:R2YW'JQ6TO.6C!SRYA';3;7>RC#%W78NG%F"\IJQYM
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M[G%W"M+YTA[>"FJF 7K;-YY?3!!*FP S][I757&$M@D ,I)C('@8.J+\]"
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M F-C<2[\;_D]-;L$,#BE3'] 0H]"LS1W"?!O0I%+VQK)+%\%A4FH4Y#_=Y<
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M#:R1YSE41NZ"2_ U*?JM]WTQMH5O8LN!YT1X5JC(5"@K$5@(EI%("A>EPE:
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M&5A77-Q5)EN:HCFR3DVLH,^+HC6RHHZN5Z4<RY5A'@+ K,@CE0G3(%\9$E%
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M*,7B54W;*6P[_A13/*\S!Z.:9#[XCH9>@(_:%O^?/[U>=^9YPREZ:+8^!A]
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M,C0P.3$W7W!R92YX;6S5FEV/XC84AN]7VO_@36]:J2$$9G86-,P*,3,KU/E
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M!A7/L -Q?7$=,6RQ_0]OHUP&!TFYTP7F1=CM$?-E7NO4)?\"4$L! A0#%
M  @ KH(S67'9&Z@($P  \W,   X              ( !     &0X-CDU,C%D
M.&LN:'1M4$L! A0#%     @ KH(S68\L,02'JP  =I,$ !
M ( !-!,  &0X-CDU,C%D97@Q,2YH=&U02P$"% ,4    " "N@C-9)X96?_@"
M   1"@  $               @ 'IO@  =6AS+3(P,C0P.3$W+GAS9%!+ 0(4
M Q0    ( *Z",UFQ ^3S608  )-&   4              "  0_"  !U:',M
M,C R-# Y,3=?;&%B+GAM;%!+ 0(4 Q0    ( *Z",UE37B^1J 0  #LL   4
M              "  9K(  !U:',M,C R-# Y,3=?<')E+GAM;%!+!08
..!0 % #P!  !TS0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d869521d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="uhs-20240917.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-17_to_2024-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000352915</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="duration_2024-09-17_to_2024-09-17"
      id="Hidden_dei_AmendmentFlag_duration_2024-09-17_to_2024-09-17">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-17_to_2024-09-17"
      id="Hidden_dei_EntityCentralIndexKey_duration_2024-09-17_to_2024-09-17">0000352915</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_0">2024-09-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_2">UNIVERSAL HEALTH SERVICES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_4">1-10765</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_5">23-2077891</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_6">UNIVERSAL CORPORATE CENTER</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_7">367 SOUTH GULPH ROAD</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_8">KING OF PRUSSIA</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_9">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_10">19406</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_11">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_12">768-3300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_18">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_23">Class&#160;B Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_24">UHS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_25">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-17_to_2024-09-17" id="Fact_16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
